<DOC>
	<DOCNO>NCT02847598</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy BIIB059 reduce skin disease activity participant systemic lupus erythematosus ( SLE ) ( Part A ) , participant active cutaneous lupus erythematosus ( CLE ) without systemic manifestation ( Part B ) , investigate dose response relationship participant active SLE skin manifestation ( Part A ) . Secondary objective evaluate additional efficacy parameter BIIB059 reduce SLE disease activity .</brief_summary>
	<brief_title>Study Evaluate BIIB059 Cutaneous Lupus Erythematosus ( CLE ) With Without Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<criteria>Key 1 . All woman childbearing potential men must practice effective contraception study 4 month last dose study treatment . 2 . CLASIA â‰¥ 8 Screening Randomization . Key 1 . Active lupus nephritis moderatetosevere chronic kidney disease . 2 . Any active skin condition CLE may interfere study ( e.g. , psoriasis , nonLE skin lupus , druginduced lupus ) . 3 . History chronic , recurrent , recent serious infection . 4 . Active clinically significant viral , bacterial , fungal infection , major episode infection require hospitalization treatment parenteral antiinfectives within 4 week Screening , completion oral antiinfectives within 2 week Screening . 5 . Use immunosuppressive diseasemodifying treatment SLE initiate less 3 month prior Screening . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CLE , SLE , Cutaneous Lupus Erythematosus , Systemic Lupus Erythematosus , Lupus</keyword>
</DOC>